Ono Pharmaceutical Company, Ltd.
https://www.ono-pharma.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Ono Pharmaceutical Company, Ltd.
Deal Watch: Gilead Grows Oncology, Inflammation Pipeline With XinThera Buy
The XinThera deal gives Gilead multiple PARP1 and MK2 inhibitors. Also, Roche licenses a HER2 kinase inhibitor from Zion, Amgen partners with TScan in Crohn’s disease and Baxter sells the last of its biopharma operations – a CDMO business – for $4.5bn.
Oncology’s Hold Over The Pharma Pipeline Increases As Growth Slows
The rate of growth of the pharma pipeline slowed last year as oncology and rare diseases tightened their grip on R&D. There are also further signs of China’s rise in importance in the industry.
Record Sales For US, Canada Hydralyte Marketer Remain Under Brand's International Shadow
Hydration Pharmaceuticals Company’s Hydralyte revenues come from limited footprint in rapidly growing sports beverage market while Prestige Consumer Healthcare’s Hydralyte footprint is limited only by not competing with Hydration Pharmaceuticals in US and Canada.
Prestige Consumer Not Thirsty For Bringing International Sales Leader Hydralyte To US
Expanding Hydralyte sales to US sports beverage market might seem a likely target for PCH. But firm doesn’t plan to bring its Hydralyte products to the US, where a smaller company owns and markets the brand.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Generic Drugs
- Other Names / Subsidiaries
-
- Ono Pharma Korea Co., Ltd., Ono Venture Investment Fund I, L.P., Ono Venture Investment, Inc., Ono Pharma UK Ltd.
- Ono Pharmaceutical Co., Ltd.
- Ono Pharma Taiwan Co., Ltd.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice